Narwhal Capital Management lowered its position in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 3.8% during the third quarter, Holdings Channel reports. The firm owned 90,600 shares of the company’s stock after selling 3,577 shares during the quarter. Johnson & Johnson makes up about 1.6% of Narwhal Capital Management’s portfolio, making the stock its 11th largest holding. Narwhal Capital Management’s holdings in Johnson & Johnson were worth $23,985,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also made changes to their positions in the company. Outlook Capital Management LLC acquired a new position in Johnson & Johnson during the second quarter worth approximately $28,000. Navigoe LLC boosted its holdings in shares of Johnson & Johnson by 60.4% in the third quarter. Navigoe LLC now owns 146 shares of the company’s stock valued at $38,000 after acquiring an additional 55 shares during the period. Matrix Trust Co boosted its holdings in shares of Johnson & Johnson by 56.2% in the second quarter. Matrix Trust Co now owns 150 shares of the company’s stock valued at $38,000 after acquiring an additional 54 shares during the period. Montgomery Financial Services LLC acquired a new stake in shares of Johnson & Johnson in the second quarter valued at approximately $43,000. Finally, Hanseatic Management Services Inc. purchased a new position in shares of Johnson & Johnson during the third quarter worth approximately $52,000. 69.55% of the stock is owned by hedge funds and other institutional investors.
Insider Activity at Johnson & Johnson
In other Johnson & Johnson news, EVP Jennifer Taubert sold 15,000 shares of the stock in a transaction on Monday, August 17th. The stock was sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the transaction, the executive vice president owned 194,451 shares of the company’s stock, valued at $51,210,615.36. This represents a 7.16% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Timothy Schmid sold 33,597 shares of the firm’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total value of $9,230,439.78. Following the sale, the executive vice president owned 25,447 shares in the company, valued at $6,991,308.78. This trade represents a 56.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.16% of the stock is currently owned by insiders.
More Johnson & Johnson News
Here are the key news stories impacting Johnson & Johnson this week:
- Positive Sentiment: Oncology sales rose 16.8% to $22 billion in the first nine months of 2026, supported by established cancer drugs and new launches. Continued growth in this business could bolster revenue. J&J’s Oncology Sales Surge So Far in 2026: What Lies Ahead?
- Positive Sentiment: CAPLYTA met the primary and key secondary endpoints in a second Phase 3 study for bipolar mania, with improvement reported as early as Day 3. J&J said the two positive studies will support a planned U.S. FDA submission, adding to the drug’s potential uses. J&J eyes US nod for Caplyta in bipolar mania after second trial win
- Positive Sentiment: Investigational drug ICOTYDE met the primary endpoint in a Phase 3 trial for psoriatic arthritis, adding another encouraging pipeline result that could support future growth if confirmed and approved. Johnson & Johnson Says Icotyde in Psoriatic Arthritis Disease Meets Primary Endpoint in Phase 3 Study
- Neutral Sentiment: A valuation analysis questioned whether JNJ’s price reflects the cash flow it may generate, noting its 108.1% return over three years. It raises a caution for investors but does not establish that the shares are overvalued. Is Johnson & Johnson (JNJ) Below Fair Value On Cash Flow?
- Negative Sentiment: Pomerantz LLP announced an investigation into claims on behalf of JNJ investors. The notice provides few details and is not a finding of wrongdoing, but it introduces potential legal uncertainty. Investor Alert: Pomerantz Law Firm Investigates Claims
Johnson & Johnson Price Performance
Shares of NYSE:JNJ opened at $280.90 on Wednesday. The firm has a market capitalization of $676.21 billion, a price-to-earnings ratio of 42.56, a price-to-earnings-growth ratio of 2.79 and a beta of 0.22. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.02 and a quick ratio of 0.74. The business’s 50 day simple moving average is $266.49 and its 200-day simple moving average is $248.93. Johnson & Johnson has a 12 month low of $189.05 and a 12 month high of $283.25.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last released its quarterly earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.53 by $0.06. The business had revenue of $25.40 billion during the quarter, compared to the consensus estimate of $25.38 billion. Johnson & Johnson had a return on equity of 31.64% and a net margin of 16.20%. The business’s revenue was up 5.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.80 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, equities analysts forecast that Johnson & Johnson will post 11.12 earnings per share for the current fiscal year.
Johnson & Johnson Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be given a dividend of $1.34 per share. The ex-dividend date is Tuesday, November 24th. This represents a $5.36 dividend on an annualized basis and a yield of 1.9%. Johnson & Johnson’s dividend payout ratio (DPR) is 81.21%.
Analyst Ratings Changes
A number of equities analysts have recently commented on JNJ shares. Stifel Nicolaus set a $260.00 target price on shares of Johnson & Johnson in a report on Wednesday, July 15th. The Goldman Sachs Group reiterated a “buy” rating and set a $282.00 price target on shares of Johnson & Johnson in a research note on Thursday, July 16th. Scotiabank reissued an “outperform” rating and set a $305.00 price objective on shares of Johnson & Johnson in a research report on Thursday, July 16th. HSBC lifted their price objective on shares of Johnson & Johnson from $290.00 to $320.00 and gave the company a “buy” rating in a research note on Thursday, September 10th. Finally, Weiss Ratings cut shares of Johnson & Johnson from a “buy (b+)” rating to a “buy (b-)” rating in a report on Friday, October 23rd. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have issued a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $275.92.
View Our Latest Stock Report on JNJ
About Johnson & Johnson
Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.
Featured Articles
- Five stocks we like better than Johnson & Johnson
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
